deaths (OS)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 0.83
cemiplimab vs. Standard of Care (SoC) 1 0.57
durvalumab alone vs. Standard of Care (SoC) 1 0.76
nivolumab alone vs. Standard of Care (SoC) 2 1.07
pembrolizumab alone vs. Standard of Care (SoC) 4 0.74